<DOC>
	<DOCNO>NCT01497145</DOCNO>
	<brief_summary>This multicenter , Randomized , Open-Label , Parallel , Comparative , Dose-Response Study Evaluate Efficacy Safety study KRN321 subcutaneous injection Adult Subjects Low- Intermediate-1-Risk Myelodysplastic Syndrome .</brief_summary>
	<brief_title>A Clinical Study KRN321 Adult Subjects With Myelodysplastic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>IPSS low intermediate1risk MDS diagnose enrollment Serum EPO concentration ≤ 500 mIU/mL Hemoglobin concentration ≤ 9.0 g/dL screen examination Previous bone marrow hematopoietic stem cell transplantation History pure red cell aplasia Cardiac condition include angina pectoris , congestive heart failure , uncontrolled arrhythmia hypertension Those increase risk thrombosis study Uncontrolled diabetes mellitus Concurrent active infection chronic inflammatory disease Other cause anemia Previous concurrent active malignancy MDS</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>